Page last updated: 2024-09-03

ci 934 and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

ci 934 has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 1 studies

*1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease. [MeSH]

*1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease. [MeSH]

Compound Research Comparison

Studies
(ci 934)
Trials
(ci 934)
Recent Studies (post-2010)
(ci 934)
Studies
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
Trials
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
Recent Studies (post-2010) (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
33023,85981,052

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abell, CW; Bembenek, ME; Brossi, A; Fritz, RR; Gessner, WP1

Other Studies

1 other study(ies) available for ci 934 and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

ArticleYear
Interaction of monoamine oxidase B with analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine derived from prodine-type analgesics.
    Journal of medicinal chemistry, 1986, Volume: 29, Issue:4

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Anti-Infective Agents; Drug Interactions; Fluoroquinolones; Humans; Liver; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pyridines; Quinolines; Structure-Activity Relationship

1986